Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) announced a follow-on multi-system order from Samsung Biologics on March 12, 2026 to expand deployment of the Growth Direct platform.
The order strengthens the companies' partnership and supports Samsung's expansion of automated microbial quality control across its manufacturing network, aiming for faster results, greater accuracy, and improved data integrity.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
RPID gained 6.05% while peers were mixed: PROF, SERA, and LNSR were up, OWLT and RCEL were down. Only SERA appeared in the momentum scanner, suggesting today’s move is more company-specific than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Conference participation | Neutral | +6.0% | Participation in KeyBanc healthcare forum with virtual Q&A webcast. |
| Feb 26 | Conference participation | Neutral | -3.1% | Planned presentation at TD Cowen healthcare conference with webcast. |
| Feb 24 | Earnings timing | Neutral | +6.3% | Announcement of Q4 and full-year 2025 results date and webcast. |
| Feb 12 | Equity inducements | Neutral | +2.8% | Inducement RSUs and options grants to new hires under Nasdaq Rule 5635(c)(4). |
| Jan 13 | Prelim revenue update | Positive | +21.1% | Record preliminary Q4 and 2025 revenue with increased Growth Direct placements. |
Recent news, especially revenue and system placement updates, has often coincided with positive price reactions, while routine conference announcements show more mixed reactions.
Over the past few months, RPID has highlighted growth in its Growth Direct® installed base and revenue, including record preliminary unaudited Q4 2025 revenue of $11.3M and full-year 2025 revenue of $33.6M. Announcements about conferences and forums on Feb 26 and Mar 10 had mixed price responses, while the preliminary revenue update on Jan 13 drove a 21.05% gain. Today’s multi-system order from Samsung Biologics aligns with this trajectory of expanding system placements.
Market Pulse Summary
This announcement highlights a follow-on multi-system order from Samsung Biologics, reinforcing adoption of RPID’s Growth Direct® platform across a major CDMO’s manufacturing network. It follows record preliminary 2025 revenue of $33.6M and expanding system placements, suggesting continued commercial traction. Investors may watch upcoming finalized 2025 results, additional large-customer orders, and trends in insider activity to gauge how effectively this partnership translates into sustained revenue and recurring usage.
Key Terms
microbiology medical
contract development and manufacturing organization (cdmo) medical
AI-generated analysis. Not financial advice.
Companies deepen partnership to advance automated, integrated microbiology quality control
LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced a new multi-system order from Samsung Biologics for its Growth Direct platform.
This follow-on order builds on the companies’ existing partnership and supports Samsung’s continued expansion of the Growth Direct platform to automate microbial quality control across its manufacturing network.
“Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and we’re pleased to strengthen our partnership with this new multi-system order,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “Their integrated plant design embeds advanced automation and digitalization capabilities, including seamless connectivity across operations - to consistently deliver high productivity and quality. The Growth Direct platform enhances that foundation by delivering faster time to results, greater accuracy, and stronger data integrity. We look forward to supporting Samsung as it continues scaling its next-generation manufacturing operations.”
To learn more about the Company and the Growth Direct platform please visit: Rapid Micro Biosystems.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the expanded deployment of the Company’s Growth Direct platform.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; competition within the Company’s industry; the Company’s ability to maintain its manufacturing operations; risks related to third-parties; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility on the Company’s business and operations; and the other important factors outlined under the caption “Risk Factors” in the Company’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 7, 2025, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Rapid Micro Biosystems Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Rapid Micro Biosystems Media Contact: media@rapidmicrobio.com
FAQ
What did Rapid Micro Biosystems (RPID) announce about Samsung Biologics on March 12, 2026?
How will the Growth Direct order from Samsung Biologics affect RPID's commercial traction?
What benefits did Rapid Micro say Growth Direct delivers for Samsung Biologics?
Is the Samsung Biologics order a new partnership or an expansion for RPID?
Does the March 12, 2026 RPID announcement disclose the order value or system count?
Where can investors learn more about Rapid Micro's Growth Direct platform after the Samsung order?
